Regeneron inks deal with Telix for radiopharmaceutical therapies
Source: SeekingAlpha
2026-04-13 08:30:20 ET
More on Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
- Regeneron: Fairly Valued Now After A Stellar Upswing
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Sanofi, Regeneron’s Dupixent approved in EU for young children with chronic urticaria
- Regeneron expects ~$102M in Q1 pre-tax IPR&D charges
Read the full article on Seeking Alpha
For further details see:
Regeneron inks deal with Telix for radiopharmaceutical therapies
Telix Pharmaceuticals Limited
NASDAQ: TLX
TLX Trading
-1.16% G/L:
$9.39 Last:
206,785 Volume:
$9.50 Open:
TLX Latest News
June 01, 2026 05:00:00 pm
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
TLX Stock Data
$2,423,405,271
305,469,565
N/A
8
N/A
Biotechnology & Life Sciences
Healthcare
US
Victoria
